Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Specific PET Radioligand Binding To Translocator Protein

Trial Profile

Evaluation of Specific PET Radioligand Binding To Translocator Protein

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RP 52028 (Primary) ; XBD 173
  • Indications Neurological disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 17 Jun 2016 Status changed from suspended to completed.
    • 07 May 2016 Status changed from recruiting to suspended.
    • 20 Jan 2016 Change in treatment table: Dose of blocking agent Emapunil decreased from 45mg to 15mg as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top